Drug dissolution in any solution is a static feature and drug dissolution rate is a trait that is primarily related to bioavailability. The primary goal of this study is to develop carbamazepine (CBZ) tablets that dissolve quickly. CBZ is an anti-epileptic medication that belongs to the Biopharmaceutical Categorization System (BCS) Class-II and is used to treat epilepsy and neuropathic pain by inhibiting use-dependent sodium channels. By using a direct compression process, CBZ fast disintegrating tablets were made using various concentrations of crospovidone in various combinations as superdisintegrants. Hardness, friability, thickness, wetting time, disintegration time and in-vitro drug release were all assessed as part of the overall formulation. The dissolution study, solubility, partition coefficient, pH adjustment, particle size reduction, complexation, drug dispersion and solubilisation by surfactant and other disintegration tests are all performed on the manufactured CBZ tablet. The drug release mechanism was discovered to be Non-Fickian Diffusion, first order release type, in the improved formulation, which followed Higuchi's kinetics. The optimized formulation F5 may be utilized for the successful therapy of Epilepsy, Convulsions, Tremors and Neuropathic Pain based on assessment factors. This may increase patient compliance by demonstrating quick action through disintegration without difficulty ingesting or adverse effects, resulting in a better therapeutic outcome. Also, the formulation's per-oral cost will be reduced drastically.
Loading....